Is Innova Captab overvalued or undervalued?

As of 3 November 2025, the valuation grade for Innova Captab has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 35.82, an EV to EBITDA of 25.09, and a ROE of 13.37%.
Innova Captab's valuation stands out against its peers, such as Sun Pharma, which is considered expensive with a PE of 35.62, and Cipla, which is also attractive with a significantly lower PE of 22.44. The company's PEG ratio of 1.00 suggests it is reasonably priced relative to its growth prospects. Notably, while Innova Captab has experienced a year-to-date decline of 26.41%, it has outperformed the Sensex in the past week, reinforcing the attractiveness of its current valuation.